Company intelligence / Profile preview

Enteron Pharmaceuticals

New York City, New York, United Statessec.gov ↗

Ownership: Private
Development stage: Other

Overview

Enteron Pharmaceuticals, Inc. appears to have been a Delaware-based biotechnology company referenced historically as a wholly-owned subsidiary of Soligenix (formerly DOR BioPharma)[3], with an address at 787 Seventh Avenue, New York, NY 10019[5]. There are no recent press releases or clinical updates indicating ongoing operations or active drug development programs. The company does not appear to be currently active and has no known products on the market nor any pipeline disclosed publicly since its mention in legacy SEC filings from over a decade ago[3][5].

Industry: Biotech

Beyond the preview

Go deeper on Enteron Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enteron Pharmaceuticals.

Explore the full profile